The
EMA’s safety feature provisions enter into force on 9 February 2019. Member
states are required to implement the new falsified medicines safety features
for almost all prescription-only medicines which aim to prevent falsified
medicinal products from entering the pharmaceutical supply chain. The safety
features are placed on the packaging of the respective medicinal products by
the pharmaceutical manufacturer and consist of the following:
a
unique identifier, in the form of a 2D data matrix barcode, allowing the
verification of the authenticity and the identification of an individual pack
of a medicinal product
anti-tampering
device
For
further details, see the MHRA blog: https://mhrainspectorate.blog.gov.uk/2019/02/08/falsified-medicines-directive-safety-features/
Posted by Dr. Tim Sandle,
Pharmaceutical Microbiology
No comments:
Post a Comment
Pharmaceutical Microbiology